Piramal Pharma narrowed its net loss to Rs 89 crore in Q1FY25 from a net loss of Rs 99 crore in the corresponding quarter of the previous year.
Revenue from operation rose 12% year-on-year (YoY) to Rs 1,951 crore in Q1FY25.
EBITDA rose 31% YoY to Rs 224 crore while EBITDA margins expanded 100 basis points to 11%.
The contract research and manufacturing services (CDMO) revenues rose 18% YoY to Rs 1057 crore led by order inflow momentum, especially for on-patent commercial manufacturing.
The complex hospital generics segment grew 2% YoY to Rs 631 crore and India consumer health business gained 10% to Rs 264 crore.
\”We delivered a healthy revenue growth accompanied by over 170bps YoY expansion in EBITDA margin driven by favorable revenue mix and cost optimization initiatives,\” said Nandini Piramal, chairperson, Piramal Pharma.
\”Historically our H2 outperforms H1, both in terms of revenue and profitability, and we expect this trend to continue in FY25,” Piramal added.
#sr_widget.onDemand p, #stock_pro.onDemand p{font-size: 14px;line-height: 1.28;}
.onDemand .live_stock{left:17px;padding:1px 3px 1px 5px;font-size:12px;font-weight:600;line-height:18px;top:9px}
#sr_widget.onDemand .sr_desc{margin:0 auto 0;}
#sr_widget.onDemand .sr_desc{color: #024d99;margin-top:10px;}
#sr_widget.onDemand .crypto .live_stock .lb-icon{8px 6px 5px 3px !important}
#sr_widget.crypto.onDemand a.text{border-bottom:1px solid #ccc;padding-bottom:5px;display:block;width:100%}
#sr_widget.onDemand .sr_desc .text p, #stock_pro.onDemand .sr_desc .text p{font-size:12px;font-weight:400;}
